Lisata Therapeutics Inc.
$ 1.06
-0.93%
07 Aug - close price
- Market Cap 9,743,800 USD
- Current Price $ 1.06
- High / Low $ 1.08 / 1.04
- Stock P/E N/A
- Book Value 1.20
- EPS -1.86
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.50 %
- ROE -0.91 %
- 52 Week High 5.07
- 52 Week Low 0.99
About
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing cellular therapies to reverse disease and/or promote regeneration of damaged tissue. The company is headquartered in Basking Ridge, New Jersey.
Analyst Target Price
$4.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-11 | 2026-03-12 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-12 | 2024-08-12 | 2024-05-09 | 2024-02-29 | 2023-11-02 |
| Reported EPS | -0.54 | -0.3344 | -0.3344 | -0.49 | -0.54 | -0.55 | -0.55 | -0.59 | -0.61 | -0.65 | -0.66 | -0.65 |
| Estimated EPS | None | 0 | -0.625 | -0.53 | -0.65 | -0.53 | -0.76 | -0.75 | -0.75 | -0.72 | -0.89 | -0.93 |
| Surprise | 0 | -0.3344 | 0.2906 | 0.04 | 0.11 | -0.02 | 0.21 | 0.16 | 0.14 | 0.07 | 0.23 | 0.28 |
| Surprise Percentage | None% | None% | 46.496% | 7.5472% | 16.9231% | -3.7736% | 27.6316% | 21.3333% | 18.6667% | 9.7222% | 25.8427% | 30.1075% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LSTA
2026-08-06 05:42:13
Lisata Therapeutics has announced a drastic workforce reduction of approximately 72% to cut costs and explore strategic options, expecting $1.2 million in severance costs. This move follows the termination of its EVP of R&D and CMO, Dr. Kristen K. Buck, and a retention bonus for James Nisco, Senior VP of Finance. Additionally, the company has sued Kuva Labs Inc. for alleged breach of a merger agreement, adding to its operational and strategic uncertainties.
2026-08-04 19:39:58
Lisata Therapeutics has announced a 72% workforce reduction and initiated legal action against Kuva Labs for an alleged breach of a merger agreement. These actions follow the collapse of a planned merger between the two companies. Lisata Therapeutics claims Kuva Labs failed to uphold the merger terms, leading to the deal's dissolution and subsequent layoffs.
2026-08-04 17:44:11
Lisata Therapeutics announced an update following the termination of its merger agreement with Kuva Labs Inc. Lisata has filed a lawsuit against Kuva for breach of the merger agreement, seeking damages and a $2 million termination fee. The company's Board of Directors is evaluating strategic alternatives to enhance stockholder value and has implemented a 72% reduction in its full-time workforce to reduce operating expenses and preserve cash.
2026-08-04 17:39:58
Lisata Therapeutics has filed a lawsuit against Kuva Labs Inc. and its subsidiary in Delaware, seeking damages and a $2 million termination fee following the termination of their merger agreement. Concurrently, Lisata has reduced its workforce by approximately 72% to cut operating expenses and preserve cash, while its Board evaluates strategic alternatives for enhancing stockholder value. The company develops therapies for advanced solid tumors, with its product candidate certepetide designed to improve the targeting of anti-cancer drugs.
2026-08-04 15:39:58
Lisata Therapeutics, Inc. (LSTA) has filed an 8-K report detailing a major workforce reduction of approximately 72% as part of a cost-cutting initiative to explore strategic options. The company also announced legal action against Kuva Labs Inc. for an alleged breach of a merger agreement and a retention bonus agreement with James Nisco to maintain key personnel during this transition period. These significant developments indicate Lisata is undergoing a crucial strategic shift that could materially impact its share price.
2026-08-04 15:39:58
Lisata Therapeutics (LSTA) has initiated legal proceedings against Kuva Labs and its subsidiary following the termination of their merger agreement, seeking a $2 million termination fee and damages for shareholders. Concurrently, Lisata is exploring strategic alternatives, including potential sales or liquidation, and has significantly reduced its workforce. The company faces valuation challenges with a high Price-to-Sales ratio and weak overall fundamentals, as indicated by a GF Score™ of 27 out of 100, though one guru has recently increased their stake.
